Accutane Pregnancy Exposure May Have Increased Under Risk Management Plan, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
During the first year of the SMART program, there were 120 pregnancy exposures, compared to 127 in the year prior to implementation of Roche's enhanced risk management program. The 23% decrease in prescriptions for the severe acne treatment suggests a relative increase in exposure.
You may also be interested in...
Accutane/Generics Risk Program Should Include Mandatory Follow-Up Survey
FDA advisory committee suggests enhancements to Roche's SMART program to better prevent pregnancies. The proposal calls for a shared brand/generic system for patient registration.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).